coils are from a company that we shall refer to for purposes of this analysis as Company A. The pricing policy of this company is different from that of another company (referred to as Company B), and this could have major cost implications. We sought to model a cost comparison to show potential cost savings with the use of a price capitation model using Company B products versus Company A products. We used clinical decision analysis to build a decision tree and compared our current expenditure on endovascular coils to the corresponding expenditure if a capped-price model were implemented.
Methods
We retrospectively reviewed coil and cost data for 148 patients who underwent coil embolization from January 2015 through September 2016. For 128 of the 148 patients, we used coils from our most frequently used provider (Company A). Data on the length and number of coils used in all patients were collected and analyzed. Based on our mean values for treated aneurysm size and total number of coils used and based on the median of the total length of coils used, we calculated the probabilities of a treated aneurysm having a size (maximum dimension) ≤ 10 mm or > 10 mm (mean 6.7 mm), the total number of coils used for a case being ≤ 5 or > 5 (mean 7.3), and the total length of coils used for a case being ≤ 50 cm or > 50 cm (median 42 cm). These values were selected to best represent the mean/median values from our data. We calculated the mean cost of the currently used coils for all possible combinations of events with the above probabilities.
The total length of coils used was analyzed, because the greater the volume of small-length coils used, the greater the financial advantage to the company. Also, the greater the number of coils used, the longer the procedure and fluoroscopy time. Although we did not take into account any cost other than the hospital cost for the coils, the financial difference associated with coil length is emphasized in our model design.
We used clinical decision analysis techniques to build a decision tree and compared our current expenditure on endovascular coils with that of implementing a capped-price model. In the model, the branch depicting the new cappedprice model used the same events and probabilities as the prevalent strategy to calculate its cost. The cost used under the capped policy was $4000. Company B proposed this price based on their internal data for the mean number of coils used per case on a national basis in relation to their current price per coil. We were not involved in this decision. We report our results on the calculated expected value of the new strategy in comparison with the current one. We also report the results of multiple 1-way sensitivity analyses by applying plausible ranges to the probability and cost variables. We then report the results of a Monte Carlo probabilistic sensitivity analysis, which applies individual distributions to simultaneously examine all variables to confirm the robustness of model results.
Using TreeAge Pro decision-analysis software (TreeAge Software), we constructed a decision model. The following steps depict the components of our decision analysis.
1. The question: Given our calculated probabilities of treating aneurysms with a maximum dimension ≤ 10 mm or > 10 mm, using a number of coils ≤ 5 or > 5 per case, and using a total length of coils ≤ 50 cm or > 50 cm for a given case, we sought the cost-minimizing option between using our most commonly used coils from Company A versus switching to the capped-price policy of Company B.
2. The model: We built a decision tree, with the 2 strategies at the square decision node. We added circular chance nodes from each strategy, containing the probabilities of aneurysm size, number of coils used, and total length of coil used until the outcome (the final payoff or total cost of coils used) was reached at the triangular terminal nodes.
3. The outcome values and probabilities: All probabilities were calculated based on our data from 148 consecutive cases of intracranial aneurysms treated over a period of 21 months. We assigned the hospital cost for coils for each event to the relevant nodes to carry out an economic analysis from the hospital perspective. The costs of coils from Company A reflect true opportunity costs for coils to the hospital and not charges or reimbursement for coils. Table 1 depicts the probabilities and ranges used in the decision model. Table 2 depicts the cost amounts and ranges used in the decision model for the different events.
4. Identify the best strategy: We then "fold back" the decision tree to determine the expected value for each strategy. The favored strategy was the one with the lower cost. 5. One-way sensitivity analysis: We varied each cost and probability individually between best-and worst-case values. We constructed a tornado diagram to depict all 2-way sensitivity analyses in a single image, showing the minimum and maximum differences in costs associated with each parameter's variation.
6. Probabilistic sensitivity analysis: To be able to vary all involved variables simultaneously (in contrast to 1-way sensitivity analysis in which only 1 variable was varied at a time), we performed Monte Carlo probabilistic sensitivity analysis in which 1000 iterations of calculating the cost difference between the 2 strategies were performed. For each of the 1000 iterations, the value for every variable depicted in Tables 1 and 2 was drawn randomly from its constructed distribution. We used beta distributions for probabilities and triangular distributions for cost variables.
7. Assumptions: We assumed that the effectiveness of treating a patient with coils from Company A or Company B was the same. This was a cost-minimization study. In interpreting the results, we also assumed that all neurointerventionists at our institution would switch to using coils from Company B after implementing the capped policy.
Results
A total of 148 patients underwent coil embolization for treatment of intracranial aneurysms during the 21-month period from January 2015 through September 2016. These cases included all aneurysms treated with coils during this period. In 95 (64%) of the 148 cases, the patients presented with a rupture, while 53 patients (36%) were treated electively. The mean aneurysm size was 6.7 mm (SD 3.5 mm, range 2.5-22 mm) ( Table 3) . A total of 1061 coils were used from a total of 4 different providers. For the 128 cases in which only coils from Company A were used, the mean cost was $10,224 (SD $5249, range $1665-$26,589). Since the standard deviation of the total length of coils used, for all coils, was more than the mean value for that variable, we report the median, which was 42 cm (range 5.4-516 cm). The median length of Company A coils used was 49 cm (range 6-516 cm).
The calculated probability of treating an aneurysm ≤ 10 mm was 0.83, that of using ≤ 5 coils was 0.42, and that of using a total coil length ≤ 50 cm was 0.89. The expected value of using the capped policy was calculated to be $4000, a cost savings of $6564 in comparison with using the price of Company A. Figure 2 depicts the decision tree.
Sensitivity Analysis: 1-Way
Varying all parameters individually through the ranges shown in Tables 1 and 2 yielded just 1 parameter (capitation cost of Company B) that decreased the cost difference between the 2 strategies to zero. The capped policy was cost saving if its cost was less than $10,500. With variation within plausible ranges (Tables 1 and 2) , none of the other parameters caused the cost of purchasing from Company A to become less than cost with the capped policy. This is depicted as a tornado diagram in Fig. 3 .
Sensitivity Analysis: Monte Carlo
For the multiway analysis, we performed Monte Carlo (probabilistic) sensitivity analysis. Monte Carlo sensitivity analysis can simultaneously vary all uncertain parameters over a range of values and a probability distribution within that range for each parameter, allowing estimation of the relative likelihood of resulting cost differences. In this analysis, parameter values were chosen randomly for 1000 iterations. Beta distributions were constructed for 
FIG. 1. Bar graph depicting the number of coils used from all providers.
Figure is available in color online only.
FIG. 2.
Folded-back decision tree depicting the expected value of each strategy along with the probabilities and cost for each event. An = aneurysm; p = probability. Figure is available in color online only.
probabilities, and for costs we used triangular distributions (commonest = baseline value, minimum and maximum ends of the ranges in our cost data). In this analysis, the lowest cost difference seen was $2750. The cumulative probability of these cost differences is graphed in Fig. 4 . Monte Carlo probabilistic sensitivity analysis thus predicted a total cost savings in 148 cases ranging from a minimum of $407,000 to a maximum of $1,799,976.
Discussion
In our current health system, we are increasingly required to prove value in what we do. Frequently, more is spent during a hospitalization for an uncomplicated endovascular treatment of an unruptured aneurysm than its Medicare reimbursement. All costs in excess of this reimbursement represent a financial loss to the institution. The more expensive the coil, the more rapidly this loss multiplies.
A 2012 article in the New England Journal of Medicine argues that when physicians consider costs, they are indeed serving the real interests of individual patients. 5 It is now abundantly evident that physicians and hospitals are dependent on each other's financial viability. Supplies and devices accounted for 24% of the increase in hospital costs per discharge from 2001 to 2006, 2 so it is important that hospitals begin to partner with physicians to target supply and device expenses.
Governments, policy makers, researchers, and payers are now relying on cost studies to make decisions on the value of new modalities. We performed a cost-minimization study and calculated the economic impact of implementing a capped-price policy versus paying per coil at our institution. We used the hospital perspective and based our calculations on the cost of coils to the hospital. Costs reflect true opportunity costs to the hospital for coils bought and not charges or reimbursement for coil cost. We assumed that the effectiveness of using coils from either strategy was the same.
Clinical decision models and Monte Carlo probabilistic analysis are very strong tools for comparing the costs of 2 strategies with similar effectiveness. Since we used both 1-way and multiway probabilistic sensitivity analyses, wherein all involved variables were ranged with an exhaustive set of plausible ranges, the values of an aneurysm size of ≤/> 10 mm, total number of coils used of ≤/> 5, and total length of coils used of ≤/> 50 cm served as good markers to calculate our initial probabilities. These values were also not selected arbitrarily but were based on the means (aneurysm size and total coils used) or median (length of coil used) from our own data set. Since 7 mm is the average size of a treated aneurysm, one could argue that the base case aneurysm size should be 7 mm rather than 10 mm. The advantage of using the Monte Carlo probabilistic sensitivity analyses is that it accounts for the probabilities of an aneurysm being less than 10 mm, with the probabilities being drawn from a distribution of aneurysm size. This exhaustively accounts for the situation in which an aneurysm is ≤/> 7 mm and ≤/> 10 mm.
Kashlan et al. 1 reported on an estimated cost savings of $76,732 after implementing a standardized coil price, calculated by dividing the total cost of all coils used in each 6-month period by the number of coils used. As an example, they state, "Coil A, which may cost $200 from Vendor 1, $400 from Vendor 2, $1000 from Vendor 3, and $800 from Vendor 4, would have an average shelf price of $600." It is interesting to note that all these vendors agreed to the policy (without agreeing to publish the specifics).
This gives an idea of the cost savings that might be possible if we as physicians are willing to negotiate with the companies to bring down the cost of their products. In our experience, Company B readily agreed to the implementation of the capped policy. Also of interest was Kashlan and colleagues' finding of an almost immediate maximal effect in cost savings achieved by logging and reporting opened but unused items. We found the mean number of opened but not used coils over 148 cases was 0.7, a number small enough for us not to include it in the analytical model. We, as a rule, have always logged and reported all opened but unused items.
Cost-reduction plans such as implementing a capitation model often raise the concern that enforced pricing will limit the type of coils available to the neurointerventionists. The method of detachment, perception of efficacy, softness, etc., do influence coil choice, but no study to date has shown any single coil to be more efficacious than any other. The existing randomized trials of bioactive coils have also failed to demonstrate any difference in outcome. A long-standing concern is what to do with companies that refuse to participate, especially when their products are preferred or perceived as superior. Trials, including the MAPS (Matrix and Platinum Science) trial 3 and the Cerecyte trial, 4 have failed to show differences in efficacy or recurrence based on coil type. The HELPS (hydrogelcoated coils vs bare platinum coils) trial 6 demonstrated that hydrogel-coated coils did not reduce late aneurysm rupture or improve outcome compared with bare-metal coils. We are moving toward a total implementation of a capped policy, which will add to the competition and incentivize other companies to follow the example of Company B. Thus, all coils should become available to the surgeon at a more economical cost.
It is easy to perceive that Company B appears to have an incentive to offer more favorable pricing, but it is reasonable to assume that prices are easily obtained between institutions and that when a price is marketed to an institution, however discretely, that price will become common knowledge and used by other institutions as leverage. In our opinion, it behooves all companies to offer the lowest price possible to attain new market share or an increase in their current share.
We did not vary the coil costs of Company A above the calculated mean for each studied event. We did, however, vary the cost below the calculated mean. Despite this conservative comparison, for all iterations and in all possible sensitivity analyses, it emerged as the not-preferred policy.
No matter what the probability of treating an aneurysm ≤/> 10 mm, using a number of coils ≤/> 5, or using a total length of coils ≤/> 50 cm, it was more economical to use the capped amount of $4000 in comparison with the coils from Company A, and this remained the dominant strategy up to a cost of $10,500. This substantiates the significant cost difference between the 2 strategies and explains the resulting cost savings.
The following limitations of our study must be taken into consideration when interpreting the results. We chose not to discuss rates of occlusion, complications, or recanalization and the attending cost, as we presumed equal efficacy between the coils. We do plan to explore complica- tions and recanalization in a future manuscript. Currently we do not have enough follow-up. There was a lack of blinding to determine the coil to be used by the surgeon.
We treated all aneurysms to complete occlusion to the best of our abilities. No aneurysm was intentionally subtotally coiled. We have not retreated a single patient from this cohort, and we continue to follow the patients both angiographically and clinically.
The findings from this study serve as an impetus to explore further cost-saving strategies in aneurysm coiling. A few strategies that we are exploring include use of different catheters and wires, observation of patients with unruptured aneurysms in a stepdown unit instead of an intensive care unit, judicious use of follow-up imaging, and treating large aneurysms with flow diverters instead of coiling. Clinical decision analysis also opens doors to explore other opportunities to save costs in endovascular therapy, such as in carotid artery stenting (comparison of stents, balloons, wires, distal protection devices) and thrombectomy (use of stent retrievers vs aspiration).
Conclusions
In a comparison of a capped-price policy versus the cost of coils from our current provider, our decision model and probabilistic sensitivity analysis predicted a minimum of $407,000 to a maximum of $1,799,976 in cost savings in 148 patients through adoption of a In a comparison of a capped-price policy for coils. This study should provide impetus to explore coil cost capitation as a cost-minimization strategy in endovascular surgery for coil embolization of intracranial aneurysms.
